Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: Cancer Res. 2008 Nov 15;68(22):9394–9403. doi: 10.1158/0008-5472.CAN-08-2815

Figure 5. Perifosine and TRAIL combination is synergistic in AML primary cells with activated Akt.

Figure 5

A: cells from patient M4#1 were treated for 48 hr with either single agent alone or in combination at the indicated concentrations. Cell viability was analyzed by MTT assays. B: Annexin V-FITC/PI staining analysis of cells from patient M4#1 treated with either perifosine or TRAIL alone and with two drugs together for 48 hr. The numbers in the lower right quadrants correspond to the percentage of cells which are Annexin V-positive and PI-negative (early apoptotic cells). C: flow cytometric analysis showing surface expression of TRAIL receptors and CD33 in cells from patient M4#1, either untreated or treated with 4.0 μM perifosine for 24 hr. Anti-TRAIL receptors antibodies were conjugated to PE, while anti-CD33 antibody was FITC-conjugated. D: western blot analysis for Ser 473 p-Akt, cFLIP-L, XIAP, FADD, and Ser 63 p-c-Jun in extracts from AML patient primary cells. Perifosine treatment was for 24 hr at 4.0 μM concentration. β-tubulin served as loading control.